SunTrust Robinson Humphrey Downgrades Summit Therapeutics plc (SMMT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint
June 27, 2018 7:00 AM EDTEzutromid Development to be DiscontinuedSummit to Focus on Advancing its Pipeline of New Mechanism AntibioticsConference Call Scheduled for 8:00am EDT / 1:00pm BST
OXFORD, United Kingdom and CAMBRIDGE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT) today announces PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy (DMD). PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the... More
